748 related articles for article (PubMed ID: 26109795)
1. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
2. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
3. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
5. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
6. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
7. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
8. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
9. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
11. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology.
Noor S; Rasul A; Iqbal MS; Ahmed B; Akash MSH; Qadir MI
Crit Rev Eukaryot Gene Expr; 2020; 30(3):273-278. PubMed ID: 32749114
[TBL] [Abstract][Full Text] [Related]
13. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
14. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.
Kitamura K; Que L; Shimadu M; Koura M; Ishihara Y; Wakae K; Nakamura T; Watashi K; Wakita T; Muramatsu M
PLoS Pathog; 2018 Jun; 14(6):e1007124. PubMed ID: 29928064
[TBL] [Abstract][Full Text] [Related]
15. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.
Ely A; Moyo B; Arbuthnot P
Mol Ther; 2016 Apr; 24(4):671-7. PubMed ID: 26916283
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
[TBL] [Abstract][Full Text] [Related]
17. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
18. Illuminating the Live-Cell Dynamics of Hepatitis B Virus Covalently Closed Circular DNA Using the CRISPR-Tag System.
Ding J; Yi Z; Zai W; Wu M; Chen B; Cai Q; Zhang X; Yuan Z
mBio; 2023 Apr; 14(2):e0355022. PubMed ID: 36840581
[TBL] [Abstract][Full Text] [Related]
19. HBVcircle: A novel tool to investigate hepatitis B virus covalently closed circular DNA.
Yan Z; Zeng J; Yu Y; Xiang K; Hu H; Zhou X; Gu L; Wang L; Zhao J; Young JAT; Gao L
J Hepatol; 2017 Jun; 66(6):1149-1157. PubMed ID: 28213165
[TBL] [Abstract][Full Text] [Related]
20. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
